Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH opened at $0.06 on Wednesday. Bellerophon Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.76. The stock has a market cap of $684,880.00, a P/E ratio of -0.07 and a beta of 0.73. The company has a 50-day moving average of $0.06 and a two-hundred day moving average of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.